Bayer - Top 13 Ad Budgets
Company: Bayer
2007 Ad Spending: $861 million
2006 Ad Spending: $683.4 million
Breakdown
- Magazines: $102.5 million
- Newspaper: $16.1 million
- Outdoor: $900,000
- TV: $330.6 million
- Radio: $18 million
- Internet: $5.3 million
Where Bayer is spending money: Almost all of Bayer's top products enjoyed a budget boost, but the largest increases went to Bayer's contraceptives Yaz ($75.8M) and Mirena ($39.5M), which were hiked 253 percent and 209 percent, respectively.
Most of Bayer's consumer products were up as well. Aleve--the company's biggest campaign--was up 42 percent to $87 million, and Bayer's image-advertising came in third behind Yaz with a $74 million budget. One A Day, Ascensia, Alka-Seltzer and Midol rounded out Bayer's ad budgets that saw increases in 2007.
The company upped ad spending for magazines, along with newspaper, TV and local radio. Overall, Bayer's 2007 sales increased a hefty 22 percent to $44 million.
Where Bayer isn't spending money: The only big product that experienced a budget cut was the veterinary drug K9 Advantix, down 18 percent from 2006 to $18 million. The company backed off national newspaper spots and radio, as well as Internet advertising, which was down over 50 percent.
Comments
Your Aleve television ad is repulsive and insulting! It shows 3 shite people, obviously stupid, in a store trying to figure out the pain relievers. A black woman, obviously smart and all-knowing, just picks the right one off the shelf, verbally shows how smart she is and how stupid the white people are, then she walks away, leaving the white people looking even more stupid. Come on, folks! Get off the black/white thing and stop insulting groups of people. Now, I will not buy Aleve or any of your products due to the association with a repulsive, insulting ad. Please remove the ad from the air and rep[rimand the people responsible for it. thank you.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: